Plasma copeptin levels before and during exogenous arginine vasopressin infusion in patients with advanced vasodilatory shock

Minerva Anestesiologica

Volumn 76, Issue 11, 2010, Pages 905-912

  Torgersen, C ^a   Luckner, G ^b   Morgenthaler, N G ^c   Jochberger, S ^b   Schmittinger, C A ^a   Wenzel, V ^b   Hasibeder, W R ^d   Grander, W ^e   Dunser M W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c BRAHMS Aktiengesellschaft ^*  (Germany)

^d Department of Anesthesiology and Critical Care Medicine   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Arginine; Copeptin; Vasodilation; Vasopressins

Indexed keywords

ARGIPRESSIN; COPEPTIN; HYDROCORTISONE; NORADRENALIN; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; FEMALE; HEART SURGERY; HEMODYNAMICS; HUMAN; INTENSIVE CARE UNIT; ISCHEMIA; LENGTH OF STAY; MALE; MORTALITY; OBSERVATIONAL STUDY; OPEN STUDY; PREDICTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SEPTIC SHOCK; SKIN DEFECT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; VASODILATATION;

AGED; ARGININE VASOPRESSIN; CRITICAL ILLNESS; ENDPOINT DETERMINATION; FEMALE; GLYCOPEPTIDES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SHOCK; TREATMENT OUTCOME; VASODILATION;

EID: 78649461431     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Jochberger S, Dörler J, Luckner G, Mayr VD, Wenzel V, Ulmer H et al. The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med 2009;37:476-82.
2. Jochberger S, Velik-Salchner C, Mayr VD, Luckner G, Wenzel V, Falkensammer G et al. The vasopressin and copeptin response in patients with vasodilatory shock after cardiac surgery: a prospective, controlled study. Intensive Care Med 2009;35:489-97.
3. Jochberger S, Zitt M, Luckner G, Mayr VD, Wenzel V, Ulmer H et al. Postoperative vasopressin and copeptin levels in noncardiac surgery patients: a prospective controlled trial. Shock 2009;31:132-8.
4. Landry DW, Levin HR, Gallant EM, Asthon RC Jr, Seo S, D'Alessandro D et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-5.
5. Dünser MW, Hasibeder WR. Dear vasopressin, where is your place in septic shock? Crit Care 2005;9:134-5.
6. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med 2004;30:1276-91.
7. Kluge M, Riedl S, Erhart-Hofmann B, Hartmann J, Waldhauser F. Improved extraction procedure and IRA for determination of arignine-8-vasopressin in plasma: role of premeasurement sample treatment and reference values in children. Clin Chem 1999;45:98-103.
8. Morgnethaler NG, Struck J, Jochberger S, Dünser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008;19:43-9.
9. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-9.
10. Jochberger S, Morgenthaler NG, Mayr VD, Luckner G, Wenzel V, Ulmer H et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006;91:4381-6.
11. Westermann I, Dünser MW, Haas T, Jochberger S, Luckner G, Mayr VD et al. Endogenous vasopressin and copeptin response in multiple trauma patients. Shock 2007;28:644-9.
12. Torgersen C, Dünser MW, Wenzel V, Jochberger S, Mayr V, Schmittinger CA et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: A randomized, controlled, open-label trial. Intensive Care Med 2010;36:57-65.
13. Moreno R, Vincent JL, Matos R, Mendonca A, Cantraine F, Thijs L et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med 1999;25:686-96.
14. Szinnai G, Morgenthaler NG, Berneis K, Struck J, Müller B, Keller U et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 2007;92:3973-8.
15. Katan M, Morgenthaler N, Widmer I, Puder JJ, König C, Müller B et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008;29:341-6.
16. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 2009;116:257-63.
17. Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007;28:219-26.
18. Dünser MW, Mayr AJ, Tür A, Pajk W, Friesenecker B, Knotzer H et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 2003;31:1394-8.
19. Luckner G, Dünser MW, Jochberger S, Mayr VD, Wenzel V, Ulmer H et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005;33:2659-66.
20. Bakker HR, Dyball RE. Reduced depletion of neurophysial hormone stores by vasopressin administration in rats drinking 2% NaCl. Neuroendocrinology 1975;18:92-103.
21. Russell JA, Walley KR, Gordon AC, Cooper DJ, Hébert PC, Singer J et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009;37:811-8.